{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:33:37Z","timestamp":1790364817599,"version":"4.1.0"},"reference-count":44,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T00:00:00Z","timestamp":1543968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Relapsed or refractory non\u2010Hodgkin lymphomas (\n                    <jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>\n                    s) often carry poor prognosis and pose management challenges. We evaluated the safety and efficacy of dasatinib, a broad\u2010spectrum multi\u2010kinase inhibitor in relapsed\/refractory\n                    <jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>\n                    with correlative genomic analysis in a Phase I\/\n                    <jats:styled-content style=\"fixed-case\">II<\/jats:styled-content>\n                    trial. The study included 33 patients with various sub\u2010types of\n                    <jats:styled-content style=\"fixed-case\">NHL<\/jats:styled-content>\n                    who had received at least one prior therapy. The most common sub\u2010types were diffuse large B\u2010cell lymphoma (24%), follicular lymphoma, grade 1\/2 (21%) and peripheral T\u2010cell lymphoma not otherwise specified (\n                    <jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content>\n                    \u2010\n                    <jats:styled-content style=\"fixed-case\">NOS<\/jats:styled-content>\n                    ; 21%). Most patients were heavily pre\u2010treated, including 42% with more than four prior therapies, 67% with rituximab exposure and 24% with prior autologous transplant. In this cohort, dasatinib showed modest activity in evaluable patients with an objective response rate of 29% (7\/24) and clinical benefit rate of 71% (17\/24). In 32 patients with outcome data, median progression\u2010free survival was 3\u00a0months and median overall survival was 22\u00b74\u00a0months. There were two patients with sustained complete responses, both with\n                    <jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content>\n                    \u2010\n                    <jats:styled-content style=\"fixed-case\">NOS<\/jats:styled-content>\n                    histology. The side effect profile was consistent with prior studies, with pleural effusion being the most common non\u2010haematological toxicity. Exploratory genomic analysis showed two cases of\n                    <jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content>\n                    \u2010\n                    <jats:styled-content style=\"fixed-case\">NOS<\/jats:styled-content>\n                    with sustained response had a common mutation in\n                    <jats:italic>\n                      <jats:styled-content style=\"fixed-case\">LRRK<\/jats:styled-content>\n                      2\n                    <\/jats:italic>\n                    and high prevalence of\n                    <jats:italic>\n                      <jats:styled-content style=\"fixed-case\">FOXO<\/jats:styled-content>\n                      1\n                    <\/jats:italic>\n                    mutation in relapsed\/refractory follicular lymphoma.\n                  <\/jats:p>","DOI":"10.1111\/bjh.15702","type":"journal-article","created":{"date-parts":[[2018,12,5]],"date-time":"2018-12-05T21:14:25Z","timestamp":1544044465000},"page":"744-752","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Phase I\/\n                    <scp>II<\/scp>\n                    study of dasatinib and exploratory genomic analysis in relapsed or refractory non\u2010Hodgkin lymphoma"],"prefix":"10.1111","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8746-4240","authenticated-orcid":false,"given":"Jayadev M.","family":"Umakanthan","sequence":"first","affiliation":[{"name":"Division of Oncology &amp; Hematology University of Nebraska Medical Center Omaha NE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javeed","family":"Iqbal","sequence":"additional","affiliation":[{"name":"Department of Pathology and Microbiology University of Nebraska Medical Center Omaha NE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie L.","family":"Batlevi","sequence":"additional","affiliation":[{"name":"Lymphoma Service Memorial Sloan\u2010Kettering Cancer Center New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Bouska","sequence":"additional","affiliation":[{"name":"Department of Pathology and Microbiology University of Nebraska Medical Center Omaha NE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynette M.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Biostatistics University of Nebraska Medical Center Omaha NE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Shostrom","sequence":"additional","affiliation":[{"name":"Department of Biostatistics University of Nebraska Medical Center Omaha NE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Nutsch","sequence":"additional","affiliation":[{"name":"Division of Oncology &amp; Hematology University of Nebraska Medical Center Omaha NE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basem M.","family":"William","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine The Ohio State University Comprehensive Cancer Center (OSUCCC\u2010James) The Ohio State University Columbus OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Gregory Bociek","sequence":"additional","affiliation":[{"name":"Division of Oncology &amp; Hematology University of Nebraska Medical Center Omaha NE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Lunning","sequence":"additional","affiliation":[{"name":"Division of Oncology &amp; Hematology University of Nebraska Medical Center Omaha NE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Bierman","sequence":"additional","affiliation":[{"name":"Division of Oncology &amp; Hematology University of Nebraska Medical Center Omaha NE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas","family":"Younes","sequence":"additional","affiliation":[{"name":"Lymphoma Service Memorial Sloan\u2010Kettering Cancer Center New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James O.","family":"Armitage","sequence":"additional","affiliation":[{"name":"Division of Oncology &amp; Hematology University of Nebraska Medical Center Omaha NE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Vose","sequence":"additional","affiliation":[{"name":"Division of Oncology &amp; Hematology University of Nebraska Medical Center Omaha NE USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,12,5]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-767335"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.175"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-4175"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-100115"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14477"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-017-0010-8"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3135"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1593\/tlo.12307"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.77"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2696"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.273"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.1618"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2007.07.007"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj996"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-664649"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1478-811X-11-97"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-05-221275"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2015.08.003"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2015.08.002"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21615"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-05-0146"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13440"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2006.03.006"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23524"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00169-2"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.192"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70213-8"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI26833"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.9759"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099480"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.9260"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209510"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-643569"},{"key":"e_1_2_8_39_1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood.V104.11.20.20","article-title":"Hematologic and cytogenetic responses in imatinib\u2010resistant accelerated and blast phase chronic myeloid leukemia (CML) patients treated with the dual SRC\/ABL kinase Inhibitor BMS\u2010354825: results from a phase I dose escalation study","volume":"104","author":"Talpaz M.","year":"2004","journal-title":"Blood"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2005.03.004"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092585"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.163"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2010.0021"},{"key":"e_1_2_8_44_1","article-title":"Dasatinib induces dephosphorylation of tyrosine proteins and apoptosis in both B\u2010cell lymphoma lines and primary B\u2010cell non\u2010Hodgkin lymphoma cells in\u00a0vitro for a subgroup of patients with phospho\u2010Src (Y416) expression","author":"Zhao X.","year":"2010","journal-title":"Cancer Research"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/1042819021000032935"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15702","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T17:35:19Z","timestamp":1694712919000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,5]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1111\/bjh.15702"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15702","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,5]]},"assertion":[{"value":"2018-07-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-05","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}